Dezfulian M, Bitar R A, Bartlett J G
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
Chemotherapy. 1993 Sep-Oct;39(5):355-60. doi: 10.1159/000239147.
The in vivo activity of ceftriaxone was examined in an experimentally induced subcutaneous infection involving Bacteroides fragilis and Escherichia coli. Mice were challenged with 1 of 10 strains of B. fragilis or E. coli, or a dual combination of the two species. The efficacy was measured by a reduction in the count of viable organisms when antimicrobial treatment was initiated 1 h after challenge and continued for 5 days. Ceftriaxone exhibited impressive activity against E. coli but showed poor in vivo activity versus B. fragilis. The antimicrobial activity of ceftriaxone was influenced by the microbial interaction in our dual-isolate model. Pharmacokinetic studies showed that ceftriaxone penetrated into abscesses and achieved peak levels of about 40% of the peak serum levels. However, in abscesses infected with B. fragilis nearly all biological activity of ceftriaxone was lost.
在一项涉及脆弱拟杆菌和大肠杆菌的实验性诱导皮下感染中，研究了头孢曲松的体内活性。用10株脆弱拟杆菌或大肠杆菌中的1株，或这两种菌的双重组合对小鼠进行攻击。在攻击后1小时开始抗菌治疗并持续5天，通过活生物体数量的减少来衡量疗效。头孢曲松对大肠杆菌表现出令人印象深刻的活性，但对脆弱拟杆菌的体内活性较差。在我们的双菌株模型中，头孢曲松的抗菌活性受微生物相互作用的影响。药代动力学研究表明，头孢曲松可渗入脓肿，达到的峰值水平约为血清峰值水平的40%。然而，在感染脆弱拟杆菌的脓肿中，头孢曲松几乎所有的生物活性都丧失了。
